Clinical Trial Search

Primary: Change in Inflammation Surface Area. — 100; 100; 43; 135 percentage of the baseline surface

Primary: Percent of Eligible Participants Who Enroll — 44 percentage of participants

Primary: Frequency of Clinically Relevant Treatment Emergent ECG Changes After Intravitreal Injection of Brolucizumab 6 mg in Patients With nAMD — 0 Number of events

Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline…

Primary: Number of Participants With Freedom From Below-the-Knee (BTK) Major Adverse Limb Event and Peri-Operative Death (POD) at 30 Days Post Index Procedure. — 284; 154…

Primary: Number of Participants With Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Participants

Primary: Frequency and Severity of Suicidal Ideation Using the Columbia-suicide Severity Rating Scale (C-SSRS) — 515; 7; 3; 1 Participants

Primary: Changes From Baseline in Lipid Profile at 8 Weeks — 52; 56.1; 184.3; 181.7 mg/dL

Primary: Urogenital CT Infection — 14; 28 Participants — p=0.0256

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) — 0.294; 0.284; 0.308; 0.240 Liter

Primary: Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks) — 6; 4 Participants

Primary: Systolic Blood Pressure Variation — 26; 23; 18; 22 percentage of variation

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ) — 10.1; 11.2; 10.6; 11.1 units on a scale

Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002